Comparative Pharmacology
Head-to-head clinical analysis: LEVAQUIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus VIGAMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVAQUIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus VIGAMOX.
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER vs VIGAMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levofloxacin is a fluoroquinolone antibacterial that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby inhibiting DNA replication and transcription.
Fluoroquinolone antibiotic that inhibits DNA gyrase and topoisomerase IV, preventing bacterial DNA replication.
750 mg intravenously every 24 hours for 5 days. Alternatively, 500 mg intravenously every 24 hours for 7-14 days depending on infection.
1 drop in affected eye(s) every 4 hours while awake for 7 days; may increase to 1 drop every 2 hours on day 1.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function (creatinine clearance >80 mL/min); prolonged in renal impairment (up to 30-50 hours in severe impairment).
Terminal elimination half-life: 12-14 hours; clinically relevant for once-daily dosing
Primarily renal excretion as unchanged drug (approximately 87% within 48 hours); less than 4% as metabolites; biliary/fecal excretion accounts for <5%.
Renal: 70-80% unchanged; biliary/fecal: 15-20%
Category C
Category C
Antibiotic (Fluoroquinolone)
Antibiotic (Fluoroquinolone)